Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Humboldt Fund

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 24
Average round size
The average size of a deal this fund participated in
Portfolio companies 16
Lead investments 0
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Food and Beverage
  • Therapeutics
  • Health Care
  • Life Science

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Humboldt Fund:
Typical Co-investors
Humboldt Fund is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Humboldt Fund:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Ascendas CNTrade Group Central, Central Region, Singapore
Context Ventures District of Columbia, United States, Washington
Crescent Capital Partners Australia, New South Wales, Sydney
Environmental Data Resources Connecticut, Shelton, United States
eumo Japan, Tokyo
Green Rock Brazil, São Paulo, Sao Paulo
ITC Service Group California, Citrus Heights, United States
Jinjiang Capital Changzhou, China, Zhejiang
Juroku Bank Gifu, Gifu Prefecture, Japan
Massa Innovations England, London, United Kingdom
NBT (Next Big Thing) England, London, United Kingdom
NextAI Canada, Ontario, Toronto
Raystone Capital Beijing, Beijing, China
Terra Seoul, Seoul-t'ukpyolsi, South Korea
The Ledger Group Canada, Ontario, Toronto
Zhangjiang Science & Technology Investment Corporation China, Hunan, Zhangjiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Endpoint Health

Health Care
$52M02 Jun 2022 Palo Alto, California, United States

Ansa Biotechnologies

Life Science
$68M11 Apr 2022 Berkeley, California, United States

Affini-T Therapeutics

Health Care
$175M22 Mar 2022 Watertown, Massachusetts, United States

Finless Foods

Consumer Goods
Food and Beverage
Food Processing
$34M02 Mar 2022 Berkeley, California, United States

HAYA Therapeutics

Health Care
$5M09 Feb 2022 Lausanne, Vaud, Switzerland

Cellino Biotech

Product Design
$80M25 Jan 2022 Cambridge, Massachusetts, United States

Ansa Biotechnologies

Life Science
$5M15 Oct 2021 Berkeley, California, United States

Compound Foods

Food and Beverage
$4M07 Sep 2021 San Francisco, California, United States

Compound Foods

Food and Beverage
31 Aug 2021 San Francisco, California, United States
Compound Foods brews up $4.5M to make coffee without beans

– Compound Foods is a synthetic biology company that creates coffee without coffee beans.
– The company raised $4.5m in seed funding.
– Backers include Chris Sacca’s climate fund Lowercarbon Capital, SVLC, Humboldt Fund, Collaborative Fund, Maple VC, Petri Bio and angel investors like Nick Green, CEO of Thrive Market.

Debut Biotech Raises $22.6M in Series A Funding

– Debut Biotech is a San Diego, CA-based developer of a biomanufacturing platform harnessing cell-free enzymes.
– The company raised $22.6m in Series A funding.
– The round was led by Material Impact with participation from Cultivian Sandbox Ventures, Fine Structure Ventures, ACVC Ventures, Humboldt Fund, Cantos Ventures, as well as existing investors including KdT Ventures.
– The new capital will be used to commercialize ingredients developed from its proprietary cell-free biomanufacturing platform.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Humboldt Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: